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Abstract
Background: One out of seven patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve
replacement (TAVR) may be affected by transthyretin cardiac amyloidosis (ATTR-CA), mostly presenting with low-
flow low-gradient AS with mildly reduced ejection fraction. The complex interaction of these two pathologies poses
specific diagnostic and management challenges. The prognostic implications of this clinical intersection are not
defined yet. Moreover, whether TAVR may have a prognostic benefit in ATTR-CA patients with symptomatic severe
AS remains unclear, posing doubts on the best management strategy in this increasingly recognized subset of
patients.
Clinical case: We present a case of an 87-year old man with low-flow low-gradient severe AS, for whom a
diagnosis of ATTR-CA was suspected based on clinical and echocardiographic criteria specific to coexisting AS and
ATTR-CA. The diagnosis was eventually confirmed by positive bone tracer scintigraphy imaging. Following in-depth
Heart team discussion, integrating frailty and prognostic information from combined cardiomyopathy states, a
decision was made to manage the patient’s severe AS conservatively.
Conclusion: In the presented case, we deemed the natural history of ATTR-CA amyloidosis to negatively affect
both the patient’ prognosis and procedural risk, adversing TAVR indication despite symptomatic severe AS. No clear
evidence is currently available to guide decision making in this setting, advocating for prospective studies to clarify
if TAVR may have a prognostic benefit in ATTR-CA - and which ATTR-CA - patients.
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Background
One out of seven patients with severe aortic stenosis
(AS) undergoing transcatheter aortic valve replacement
(TAVR) may be affected by transthyretin cardiac amyl-
oidosis (ATTR-CA), mostly presenting with low-flow
low-gradient AS with mildly reduced ejection fraction
[1]. The complex interaction of these two pathologies
poses specific diagnostic and management challenges.
The prognostic implications of this clinical intersection
are not defined yet. Moreover, whether TAVR may have
a prognostic benefit in ATTR-CA patients with symp-
tomatic severe AS remains unclear, posing doubts on
the best management strategy in this increasingly recog-
nized subset of patients.
Case presentation
A 87-year old man with a presenting diagnosis of hyper-
tensive cardiomyopathy, orthostatic hypotension, moder-
ate aortic stenosis, permanent atrial fibrillation, left
bundle branch block and preserved ejection fraction (EF)
(home therapy: valsartan 80mg, bisoprolol 2.5 mg) was
admitted to our Clinic with Canadian Cardiovascular So-
ciety III angina, New York Heart Association (NYHA)
III functional class and signs of pulmonary and systemic
venous congestion (Fig. 1).
Cardiac ultrasound documented left ventricle (LV)
hypertrophy (septum 16mm, posterior wall 15mm, LV
mass index 189 g/m2) with severe concentric remodeling
(relative wall thickness 0.6), mildly reduced EF (50%), se-
verely depressed global longitudinal strain (− 3.1%) with
no relative apical sparing pattern and an average mitral
annular Tissue Doppler S′ of 5.5 cm/sec. Second degree
diastolic disfunction and severe biatrial dilatation were
also apparent. A low QRS voltage-to-LV mass ratio by
Sokolow-Lyon criteria was observed. Aortic valve evalu-
ation revealed low flow-low gradient severe aortic stenosis
(AS) (Vmax 2.6m/sec, max/mean gradient 28/16mmHg,
indexed aortic valve functional area 0.4 cm2/m2, stroke
volume index 21ml/m2)((Fig. 2), confirmed by computed
tomography scan (aortic valve calcium score 2500).
Following successful decongestion and clinical im-
provement with intravenous diuretics and vasodilators,
Fig. 1 a Chest x-ray at patient hospital admission showing lung congestion and enlarged heart shadow (top left). b Coronary angiography
showing diffuse disease with critical disease of the mid and distal left anterior descending coronary artery and of the proximal and distal
circumflex coronary artery (top right). c Electrocardiogram showing atrial fibrillation and left bundle branch block (bottom)
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coronary angiography revealed critical multivessel diffuse
disease, which was treated with complete percutaneous
revascularization (two drug-eluting stents on the left an-
terior descending and circumflex coronary arteries).
Based on the low-flow low-gradient AS phenotype in
the background of severe concentric hypertrophy, bia-
trial dilatation, S′ wave depression, conduction abnor-
malities, low QRS-voltage-to-LV-mass ratio and history
of orthostatic hypotension, a diagnosis of amyloid car-
diomyopathy was suspected. Bone tracer scintigraphy
was performed revealing high diffuse myocardial uptake
(Perugini score 3), diagnostic - in the context of an ab-
sent monoclonal protein on serum and urine exams (the
patient had negative serum and urine immunofixation,
and negative serum free light chain assay) - for trans-
thyretin cardiac amyloidosis (ATTR-CA) [2] (Fig. 3).
The patient was unsuitable for ATTR-CA specific
treatment because of current national reimbursement
policies.
A Heart Team evaluation was carried. In consideration
of the high procedural risk (EuroSCORE II 11.4%) trans-
catheter aortic valve replacement (TAVR) appeared indi-
cated for severe AS treatment. However, considering the
patient frailty (Essential Frailty Toolset score of 4/5: pre-
procedural anemia (1 point), hypoalbuminemia (1 point),
lower-extremity muscle weakness (2 points) [3]), the
presence of ATTR-CA cardiomyopathy-specific markers
of adverse prognosis (Mayo Clinic ATTR-CA stage III:
high-sensitivity troponin T = 280 ng/L, NTproBNP =
6500 ng/L [4]; echocardiographic parameters heralding
poor prognosis in ATTR-CA with severe AS: reduced
stroke volume, severely reduced global longitudinal
strain, increased filling pressures [5]), considering the
clinical stability on oral diuretics following decongestion
and revascularization and the patient preference not to
proceed to further invasive management during the
current hospitalization, the decision was made to dis-
charge the patient on heart failure medical therapy, with
an indication for TAVR re-evaluation in case of further
acute decompensation. At last (6-month) follow-up the
patient is alive, with clinical stability on medical therapy
(NYHA IIb, no angina) and no ensuing cardiac
rehospitalizations.
Discussion and conclusions
ATTR-CA is a common under recognized condition
among patients with severe AS, mostly presenting with
low-flow low-gradient AS with mildly reduced EF [1]. A
high index of suspicion is needed due to the overlapping
clinical and echocardiographic presentations of AS pa-
tients with and without ATTR-CA. Suspicion should be
based on a careful assessment of clinical features including
Fig. 2 a Transthoracic echocardiographic apical 4-chamber view showing severe LV hypertrophy with myocardial granular sparkling, biatrial
dilatation and atrial septal thickening. b Longitudinal strain analysis revealing severely impaired longitudinal systolic function without apical
sparing. c Lateral and septal mitral annular tissue Doppler showing a severely reduced average S’. d Continuous wave doppler across LV outflow
tract showing low gradient AS
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older age, male sex, bilateral carpal tunnel syndrome, ortho-
static hypotension, frequent hospitalizations for heart fail-
ure with preserved EF (prior to severe AS diagnosis) and
conduction disorders. No association with bicuspid aortic
valve disease is reported [6]. Classic echocardiographic
signs suggestive of ATTR-CA are frequently inapparent or
attributed to severe AS pathophysiology [7]. A relative lon-
gitudinal strain apical sparing pattern - while presenting
high accuracy for ATTR-CA diagnosis in patients without
severe AS - is usually absent in ATTR-CA patients with
concomitant severe AS [1]. A tissue Doppler average mitral
annular S′ of < 6 cm/s has been recently proposed as a
100% sensitive measure to screen TAVR candidates for
ATTR-CA, with more than half patients with S′ < 6 cm/s
having ATTR-CA as confirmed by bone tracer nuclear
scintigraphy [1]. Only sparse retrospective evidence is avail-
able regarding prognosis of severe AS patients with ATTR-
CA undergoing aortic valve intervention, mostly limited to
surgical replacement and suggesting a high in-hospital and
long-term mortality [7].
In this context, no solid evidence is currently avail-
able to inform the diagnostic strategies for ATTR-CA
among patients with severe AS and, more import-
antly, whether and in which ATTR-CA patients
TAVR (and which with TAVR device [8]) may have a
prognostic benefit remains unclear.
In the presented case, a comprehensive heart team
evaluation deemed the natural history of ATTR-CA to
negatively affect both the patient’s prognosis and pro-
cedural risk, leading, along with consideration of patient
preferences, to a lack of indication to TAVR during the
index hospitalization despite severe AS. At mid-term
follow-up, the patient was clinically stable without ensu-
ing decompensation episodes, accordingly, clinical
follow-up is ongoing. This management strategy, despite
based on objective functional, laboratoristic and imaging
parameters along with patient preferences, was based on
a subjective weight of the numerous elements taken into
considerations, as solid data regarding risk stratification
and management of severe AS in patients with ATTR-
CA are currently lacking. Indeed, no clear guidance to
orientate decision making in this setting is available, ad-
vocating for prospective studies to clarify if TAVR may
have a prognostic benefit in ATTR-CA - and which
ATTR-CA-patients.
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